Hutchmed (HCM) said Wednesday it has initiated a global phase 1 clinical development program for its HMPL-A251 monotherapy candidate derived from the company's ATTC platform, in patients with solid tumors.

The first patient was dosed on Tuesday in China, the company said.

Hutchmed said the primary outcome measures of the study are to evaluate the safety and tolerability of HMPL-A251 and to determine the maximum tolerated dose and recommended dose for expansion in the first phase of the trial. In the following phases, further safety evaluation and preliminary efficacy at recommended doses will be studied.

Secondary outcome measures of the study include preliminary antitumor activity, pharmacokinetic profile, and the immunogenicity of HMPL-A251, the company said.